FHL2 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a full length recombinant FHL2.
- 产品详情
- 实验流程
- 背景知识
Application
| WB, IF |
|---|---|
| Primary Accession | Q14192 |
| Other Accession | BC014397 |
| Reactivity | Human |
| Host | mouse |
| Clonality | monoclonal |
| Isotype | IgG1 kappa |
| Clone Names | 2G3-1A5 |
| Calculated MW | 32193 Da |
| Gene ID | 2274 |
|---|---|
| Other Names | Four and a half LIM domains protein 2, FHL-2, LIM domain protein DRAL, Skeletal muscle LIM-protein 3, SLIM-3, FHL2, DRAL, SLIM3 |
| Target/Specificity | FHL2 (AAH14397, 1 a.a. ~ 279 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
| Dilution | WB~~1:500~1000 IF~~1:50~200 |
| Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
| Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
| Precautions | FHL2 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. |
For Research Use Only. Not For Use In Diagnostic Procedures.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
LIM proteins contain a highly conserved double zinc finger motif called the LIM domain.
REFERENCES
Sp1 upregulates the four and half lim 2 (FHL2) expression in gastrointestinal cancers through transcription regulation. Guo Z, et al. Mol Carcinog, 2010 Sep. PMID 20607723.Four-and-a-half LIM domain protein 2 is a novel regulator of sphingosine 1-phosphate receptor 1 in CCL19-induced dendritic cell migration. K?nig K, et al. J Immunol, 2010 Aug 1. PMID 20592280.Four-and-a-half LIM protein 2 promotes invasive potential and epithelial-mesenchymal transition in colon cancer. Zhang W, et al. Carcinogenesis, 2010 Jul. PMID 20460358.Four and a half LIM domain 2 alters the impact of aryl hydrocarbon receptor on androgen receptor transcriptional activity. Kollara A, et al. J Steroid Biochem Mol Biol, 2010 Jan. PMID 19815066.The Patched dependence receptor triggers apoptosis through a DRAL-caspase-9 complex. Mille F, et al. Nat Cell Biol, 2009 Jun. PMID 19465923.
终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.
















癌症的基本特征包括细胞增殖、血管生成、迁移、凋亡逃避机制和细胞永生等。找到癌症发生过程中这些通路的关键标记物和对应的抗体用于检测至关重要。
为您推荐一个泛素化位点预测神器——泛素化分析工具,可以为您的蛋白的泛素化位点作出预测和评分。
细胞自噬受体图形绘图工具为你的蛋白的细胞受体结合位点作出预测和评分,识别结合到自噬通路中的蛋白是非常重要的,便于让我们理解自噬在正常生理、病理过程中的作用,如发育、细胞分化、神经退化性疾病、压力条件下、感染和癌症。